Sanofi Bets $1 Billion on Preclinical Next-gen Immunotherapies
Ever since Amgen’s Blincyto (blinatumomab) won the first FDA approval for a T-cell engager in 2014, companies have been rushing to enter the space. Sanofi is paying $1 billion upfront to acquire a US-based immuno-oncology company developing drugs that activate in the tumor microenvironment.